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Symposium on Ethics Dumping
Working Together to Make the World a Healthier 
Place: Desiderata for the Pharmaceutical 
Industry
KLAUS M. LEISINGER and KATE CHATFIELD
Abstract: Cross-sectorial, dynamic, and innovative partnerships are essential to resolve the 
challenges of humankind in the 21st century. At the same time, trust in each other’s integ-
rity and good will is a precondition for the solution of any complex problem, and certainly 
for the success of the United Nations Sustainable Development Agenda. Experience shows 
that a nation’s economic and social success is at its greatest if, and when, there is coopera-
tion and even cocreation involving a fair division of labor and responsibility among the 
different societal stakeholders. This paper uses Ralf Dahrendorf’s seminal work on obliga-
tions, as well as the European Commission’s Science with and for Society unit’s definition 
of responsible research and innovation (RRI), to motivate industry responsibilities to make 
the world a healthier place.
Keywords: research ethics; corporate responsibility; pharmaceutical industry; responsible 
research and innovation (RRI); low- and middle-income countries
21st Century Challenges
The most recent (2017) State of the Future report from the Millennium Project1 
paints a candid picture of the ongoing grand challenges that face humankind in 
the 21st century such as access to clean water, the rich-poor gap, sustainable devel-
opment and climate change, population growth, increasing energy demands, and 
health issues. While recent efforts have yielded certain tangible improvements 
such as an increase in life expectancy and a decrease in child mortality, poverty, 
contagious disease, and illiteracy, serious challenges remain, in particular, 
increases in the global population and in environmental degradation.
As emphasized in the Millennium Project report, all of the challenges are trans-
national in nature and they demand transinstitutional solutions; they cannot be 
addressed by any single government or institution alone and will require collab-
orative action among governments, international organizations, corporations, 
universities, nongovernmental organizations, and individuals. There are clear 
indications, from this report and others, of increasing consensus about the global 
situation and the actions needed to address the colossal challenges facing 
humankind.
A highly significant development in this regard has been the agreement of the 
Sustainable Development Goals (SDGs), which call for a concerted global effort to 
transform our world by 2030.2 The Agenda 2030 for Sustainable Development is a 
nonbinding document released by the United Nations in 2015, after considerable 
deliberations and consultations amongst 193 member states and global civil society. 
This paper arises from work undertaken for the TRUST project, funded by the European Commission 
Horizon 2020 Programme, agreement number 664771. Thanks to Doris Schroeder and Julie Cook for 
their support in the development of this paper.
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The Agenda has set 17 SDGs with 169 targets. All 17 goals are directly related 
to the 2012 document The Future We Want,3 which was agreed at the Rio+20 
Conference held in 2012. The United Nations Department of Economic and Social 
Affairs has noted:
The achievement of the 2030 Agenda for Sustainable Development and 
the Sustainable Development Goals will require all hands on deck. It will 
require different sectors and actors working together in an integrated 
manner by pooling financial resources, knowledge, and expertise. In our 
new development era with 17 intertwined Sustainable Development 
Goals and 169 associated targets as a blueprint for achieving the sustain-
able Future We Want, cross-sectorial and innovative multistakeholder 
partnerships will play a crucial role for getting us to where we need by 
the year 2030.4
Successful research and innovation, undertaken in a responsible manner, is 
a prerequisite for efforts to implement the SDGs. The necessity for cooperative 
efforts in research and innovation for successful implementation of the goals is 
clear: since the SDGs seek to address complex global problems that cannot be 
solved by single actors,5 multiple stakeholders must work together to find solutions 
and ensure that actions are taken. In particular, the “enhancement of North-South 
international cooperation on, and access to, science, technology and innovation” is 
a named target. It is part of SDG 17: “global partnerships for sustainable develop-
ment”.6 In the European Union (EU), significant emphasis is placed upon “research 
and innovation” as a key solution to Europe’s economic and social problems and 
this has become an integral part of the Europe 2020 policy structure, in the form of 
the Innovation Union flagship.7
Ethics Dumping
Progressive globalization in research and innovation may undoubtedly convey 
substantial benefits, but it can also provoke a multitude of sensitive ethical issues. 
For instance, in clinical trials, participant populations may differ greatly between 
regions in terms of usual standards of medical care, cultural beliefs and norms, 
levels of education and literacy, socioeconomic status, and access to legal systems. 
Ethical approval systems and research governance structures may vary widely 
between countries and between institutions.8 Consequently, there is a risk that 
research that is not permissible in northern, high-income countries will be con-
ducted in southern, low- and middle-income countries (LMICs) where the legal 
and regulatory frameworks for research are not as stringent. The European 
Commission (EC) has highlighted this threat, pointing out that when research is 
conducted by European organizations outside the EU, there is a risk that, without 
proper compliance structures and follow-up, ethical standards may be neglected. 
The EC has termed this practice “ethics dumping.”9 (The term “dumping,” in the 
business context, is traditionally associated with predatory pricing policies. Large 
entities can afford to undercut local competitors for a given period in order to 
drive them out of the market.) In the context of research ethics, “ethics dumping” 
can mean both the purposeful exploitation of third country research participants and 
resources and exploitation based on insufficient ethics awareness. In exploitative 
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relationships, peoples’ vulnerabilities are treated as opportunities to advance 
others’ interests or projects.10
The EU is currently funding actions to address the risk of ethics dumping from 
both public and private research, and one such action is the TRUST project.11 
TRUST aims to foster adherence to high ethical standards in research globally and 
to counteract the practice of ethics dumping, or the application of double stan-
dards in research. The will to act in collaboration across national, institutional, 
political, religious, and ideological boundaries that is necessary to address today’s 
global challenges also requires cooperation on global ethics.12 However, any mea-
sure to improve global ethical research governance and adherence to high ethical 
standards in the long term will fail if highly important stakeholders are not 
involved in the process of its development. Without sharing “ownership” of the 
process and of the outcomes of projects such as TRUST, significant stakeholders’ 
motivation to engage in fair and ethical research practices and comply with “yet 
another” set of standards and procedures cannot be presumed.
The attainment of global health and wellbeing (SDG #3) sets highly aspirational 
targets including an end of the epidemics of AIDS, tuberculosis, malaria, and other 
communicable diseases by 2030. It also aims to achieve universal health coverage 
and to provide access to safe and effective medicines and vaccines for all. This will 
entail, inter alia, support for the research and development of vaccines and medi-
cines for diseases that primarily affect LMICs. Since the private sector, particularly 
the research-based pharmaceutical industry, is the most important innovator of 
health care products, improving adherence to high ethical standards globally must 
involve this industry.
The research-based pharmaceutical industry has an enormous impact on global 
health due to its global reach and its impact on setting international standards. In 
particular, its influence upon ethical standards in clinical research in LMICs can-
not be ignored; most large, multinational pharmaceutical corporations undertake 
a proportion of their research activities, including clinical trials, in LMICs. Hence, 
the “buy in” of pharmaceutical corporation efforts to counteract ethics dumping 
and improve ethical standards in multinational, cross-cultural, collaborative 
research efforts is imperative.
The Trust Issue
It is undeniable that cross-sectorial, dynamic, and innovative partnerships are 
essential to resolve the challenges of humankind in the 21st century, but at the 
same time, trust in each other’s integrity and goodwill is a precondition for the 
solution of any complex problem and certainly for the success of the Sustainable 
Development Agenda. Without trust, as UN Secretary General António Guterres 
has said, we cannot face the difficult challenges for our world today.13 However, 
today’s overall global societal atmosphere is characterized by a lack of trust in 
fundamental institutions. Following their most recent (2017) Trust Barometer, 
global communications marketing firm Edelman concluded that “trust is in crisis 
around the world.”14 Edelman’s 17th annual survey included more than 33,000 
individuals, across 28 countries, and found that trust to do what is right had declined 
broadly across business, government, nongovernmental organizations, and media; 
the largest-ever drop in trust since they began their tracking. The same poll 
revealed a lack of credibility in regard to both business and government leadership 
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and, significantly, 82% of respondents were of the opinion that the pharmaceutical 
industry needs more regulation.
In the business sector, lack of trust arises when people either find out about 
indecent corporate behavior or perceive that harm of any kind has been inflicted, 
particularly on vulnerable human beings. Individual scandals can serve as a justi-
fication for more generalized criticisms, which further erode trust, and the internet 
abounds with examples of corporate crime. For the past 30 years, Washington, 
D.C., based Corporate Crime Reporter15 has been publishing cases of corporate 
crime in America; some recent reports involve members of the pharmaceutical 
industry. Following legal action, pharmaceutical companies have been ordered 
to pay millions of dollars to resolve allegations of violations of US acts like the 
Federal and State False Claims Act16 and the Federal Food, Drug and Cosmetic 
Act,17 as well as allegations of fraudulent behavior such as knowingly reporting to 
the government false and fraudulent prices of products.18 Without passing judge-
ment on any particular cases, it is fair to say that the international pharmaceutical 
industry currently has a public image problem19 and such cases do not help to 
(re)build trust in the industry.
Given the heterogeneity of the pharmaceutical industry (research-based and 
generic companies, companies of different sizes, each with their own unique ethos 
and different types of leadership, etc.), generalizing judgments are inappropriate. 
The sheer size and complexity of multinational corporations makes the building 
of trust across all areas of the business challenging, even if a company is operating 
with integrity.20 From the perspective of many civil society activists, the fact that 
research endeavors in the private sector are usually driven by profit motives adds 
an additional layer of skepticism. In this context, for many stakeholders from civil 
society, academia, and the media, clinical trials in LMICs, as well as access to inno-
vative medicines, are highly controversial subjects, overshadowed by a significant 
lack of trust towards the corporate actors involved.21 This poses a problem for all, 
not just the industry; the pharmaceutical industry is vital for collaborative efforts 
towards achievement of the SDGs and trust is fundamental for effective 
collaborations.
How can this problem be resolved? Between 56% and 65% of respondents in the 
previously mentioned Trust Barometer rated ethical business practices as one of the 
top five preconditions required to build trust in a company.22 Of course, “doing no 
harm” is the most important precondition for preventing the creation of distrust, 
but companies must also “do good” in order to build trust and they are increas-
ingly “expected to do more,”23 particularly with regard to those who live in 
impoverished conditions all over the world.
Indeed, many pharmaceutical companies have taken it upon themselves to 
develop strategies for the cocreation of solutions for the SDGs, making public dec-
larations about their contributions. Some have begun to report upon develop-
ments in their annual reports. For instance, for each of the 17 goals, Roche provides 
examples of efforts or agreed company goals; for goal 5, gender equality, the com-
pany aims to increase the percentage of women in leadership roles to 29% by 2020 
(from 13% in 2009).24 Pfizer declares a commitment to help achieve all 17 SDGs, but 
in particular, seven of the goals are highlighted as being closely aligned to their 
mission as a research-based biopharmaceutical company.25 Working towards goal 
6, clean water and sanitation, Pfizer describe public-private partnerships including 
the International Trachoma Initiative,26 as well as efforts to responsibly manage 
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the company’s own water consumption and disposal. Novartis has developed sev-
eral access to medicines programs and has taken steps towards achieving its 
Vision 2030 on Environmental Sustainability and 2020 targets. Overall, Novartis 
has managed to reduce its net greenhouse gas emissions by 18.7% since 2010. 
Development has also begun on an approach to capture, measure, and value the 
external economic, environmental, and social impacts created by the company’s 
activities.27 Glaxosmithkline expresses a long-term commitment to improving 
access to health care across the world. Since 2010, it has capped the prices of pat-
ented medicines and vaccines in the “least developed countries” at 25% of those in 
the EU5 (France, Germany, Italy, Spain, and the U.K.) as long as manufacturing 
costs are covered.28
From an institutional perspective, trust is a forward-looking metric. Unlike 
reputation, which is based on an organization’s historical behavior, trust is a pre-
dictor of credibility in the future.29 To rebuild trust and restore faith in the system, 
institutions must step outside of traditional business roles and work towards inte-
grated operating models that put all stakeholders (humans, animals, and the envi-
ronment), not just shareholders, at the center of their activities.30 The above 
examples demonstrate steps in this direction. In the context of clinical research, 
the stakeholders in each different location/environment may have their own 
unique perspectives, assumptions, needs, and expectations. In LMICs these can be 
heavily influenced by factors such as high disease burdens, low socioeconomic 
status, and poor environmental conditions, thereby increasing vulnerability to 
ethics dumping. These additional complexities and sensitivities demand addi-
tional care.
A Practical Approach to Corporate Responsibility
The Ralf Dahrendorf model, as suggested in his seminal work Homo Sociologicus,31 
is helpful for the gradation of corporate responsibility areas and can be visualized 
as a pyramid of responsibility levels (Figure 1). Each level consists of specific moral 
duties with their specific grade of liability as follows:
 
	 •	 	Level 1. Must-expectation (Muss-Erwartung): no positive reward for compli-
ance but negative sanction for noncompliance
	 •	 	Level 2. Ought-expectation (Soll-Erwartung): sympathy/goodwill for compli-
ance but societal rejection/exclusion for noncompliance
	 •	 	Level 3. Can-expectation (Kann-Erwartung): appreciation/esteem for compli-
ance and antipathy for noncompliance
 
Figure 1. Hierarchy of Responsibility Levels.
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The must dimension forms the base of the pyramid and comprises nonnegotiable 
corporate duties which include, for example, compliance with national law and 
regulation and avoidance of deception or fraud. This includes protection of the 
environment, as well as the health and safety of employees, customers, and neigh-
bors according to applicable law. Other duties that lie within this domain are obli-
gations to meet the expectations of shareholders and employees; shareholders 
expect a fair return on their investment and employees expect fair wages. Companies 
also add value to society by providing products and services that meet customer 
needs or enhance their quality of life. In the case of pharmaceutical corporations, 
this includes medicines and vaccines that enhance health and wellbeing.
To compete with integrity, businesses must achieve business success without 
inflicting collateral social, ecological, or political damage. This demands aware-
ness of risk factors for such damage. Ethical challenges and dilemmas do not arise 
in a vacuum, they always happen in a specific social, economic, cultural, political 
context. To manage risks effectively, one has to know them in the specificity of their 
context. For this reason, pharmaceutical companies must conduct ex ante due 
diligence processes before a clinical trial is conducted in LMICs. Only ex ante due 
diligence assessments enable responsible actors to identify and account for poten-
tial adverse/undesirable impacts on populations and to take steps to prevent, 
mitigate, and address them.
Due diligence includes assessing actual and potential vulnerabilities and 
impacts, integrating and acting upon the findings, tracking responses, and com-
municating how impacts are addressed. The initial steps in conducting an ex ante 
due diligence may be
 
	 •	 	to	identify	and	assess	the	nature of the actual and potential adverse impacts of 
business or research activities (for example, all the processes and procedures 
involved in a clinical trial and its conduct in this environment);
	 •	 	to	identify	who/what may be affected and how (for example, the participants, 
local researchers, local health personnel, and local communities). 
 
It is then possible to decide on accompanying measures to avoid or mitigate poten-
tially undesirable impacts on those identified. These processes should involve 
meaningful consultation with potentially affected groups as well as other relevant 
stakeholders. Ex ante due diligence is absolutely nonnegotiable as ignorance of 
the local context should never be used as an excuse for the exploitation of vulner-
able populations.
The ought to dimension comprises acts of responsibility that go beyond legal 
compliance in a national context. In some countries, where the quality of law is 
state-of-the-art and enforced effectively, adherence to national laws and regula-
tions goes a long way towards satisfying the requirements of responsible corpo-
rate conduct. However, in regions where this is not the case, responsible companies 
will exceed legal minima by applying higher corporate norms, for example, 
through the use of state-of-the-art environmental technology and social policies, 
even where local law would permit lower standards.
In the case of pharmaceutical corporations, the ought to responsibilities can 
include a wide range of activities such as support for broader global goals (like the 
SDGs) or support for within-country health and development goals that are rele-
vant to the local context. Another ought to responsibility in the context of clinical 
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trials in LMICs includes taking additional steps to maintain accountability and 
avoid any watering down of accountability through outsourcing. In collaborative 
work, important and sensitive tasks are often outsourced to third parties, who 
may then further outsource parts of the work to other actors. For example, in 
India, it is estimated that more than three hundred contract research organizations 
have been established, within a short time frame, to serve the requirements of 
pharmaceutical companies. Personnel within these organizations, many of whom 
are not properly qualified, may act as the local principal investigator in clinical 
studies, taking on responsibility for local management. This has resulted in seri-
ous ethical infringements such as failure to seek informed consent, recruitment of 
unsuitable participants, failure to manage side effects from the investigative treat-
ment, and the receipt of substantial incentives for timely recruitment.32,33
The totality of the must and the ought domains constitute “good management 
practices.” Acting upon these responsibilities will help to ensure a thriving business. 
Hence, there is a clear element of enlightened self-interest for corporate responsi-
bility at these levels.
On the other hand, the can dimension of corporate responsibility at the top of 
the pyramid is not obligatory either by law or by industry standards. It encom-
passes socially desirable practices and investments such as pro bono research for 
tropical and poverty-related diseases. Corporate philanthropy belongs to this 
level and is usually not bound to any direct company advantages or measurable 
financial return. In the context of pharmaceutical company work in LMICs, an 
example of a can activity might be the opening of access to unused product patents 
for the development of medicines for use in low-income settings. Currently, a sub-
stantial proportion of patents lay unused,34 yielding no return on what may have 
been years of work and significant economic investment. Redevelopment of these 
abandoned compounds could build on this prior work, meaning a potentially 
shorter path to market and focusing on addressing unmet medical needs.35 
Pharmaceutical companies can chose to open access to such patents for not-
for-profit institutions and provide a free license when suitable medicines are 
developed.
Management has no option when it comes to adhering to laws and regulations, 
and “good management practices” may be driven by enlightened self-interest, but 
corporate citizenship deliverables above and beyond a certain standard remain at 
the sole discretion of management. From a purely economic point of view, it could 
be argued that every dollar spent on corporate responsibility beyond legal require-
ments and basic standards of decency is a dollar diverted from potentially profit-
generating activity. This is why, ultimately, the top management of every company 
has to draw the line on what it can assume responsibility for. While dialogue with 
open-minded stakeholders will help to sharpen awareness about social, political, 
and environmental problems, the ultimate decision on how far a company 
extends its “responsibility frontier” remains the prerogative of informed top 
management.
Responsible Research and Innovation
The subject of corporate responsibility occupies a prominent position on the global 
corporate agenda and has significant importance as an area of business practice 
and academic inquiry.36,37 However, in comparison to other business activities, 
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company research and innovation activities have received scant attention in the 
corporate responsibility discourse. This is changing rapidly; current EU policy 
specifically underlines the importance of research and innovation in addressing 
grand challenges and, more generally, highlighting the need for a responsible 
approach to research and innovation activities.38 In this context, the EU is promot-
ing the concept of responsible research and innovation (RRI) as a key governance 
framework that underpins its considerable investment in research and technology 
development.
As a field of study and practice, RRI has gained prominence over the last decade, 
its aim being to ensure that research and innovation activities are socially accept-
able, desirable, and sustainable.39 In general terms, RRI can be thought of as a 
move towards greater inclusion and responsiveness in the governance of research 
and innovation.40 While discussion and debate about the precise nature of RRI is 
ongoing,41 there are certain recurring themes that emerge from the RRI discourse. 
These include matters such as the need for alignment of research and innovation 
with societal needs, the need to anticipate and be responsive to ethical, envi-
ronmental and societal concerns, and the need to enhance these efforts through 
engagement with a broad range of stakeholders.42,43
As the largest funder of research in Europe, the EC has a significant influence on 
research policy and it has adopted RRI as both a subject of study and a condition 
of funding.44 The concept of RRI is integral to the EC’s Horizon 2020 research 
framework program (2014-2020), and during its lifetime, Science with and for 
Society is funding research activities worth €460 million. In the EC’s view, RRI 
consists of a number of pillars that correspond to established research policy areas: 
civil society engagement, gender equality, science education, open access, ethics 
compliance, and governance.45,46 The question of how such goals can be achieved 
is typically answered with a reference to grand challenges.47 Where research 
addresses such grand challenges, it is deemed to be in the public interest and to 
fulfill the acceptability and desirability criteria of research.
The EC support for RRI may be laudable, but the promotion of RRI has, until 
recently, focused predominantly on publicly funded research, omitting a substan-
tial proportion of company-based innovation activities.48 Given that the vast 
majority of research and innovation activities occur in the private sector, such poli-
cies need to be sensitive to specific industry-related challenges, such as tensions 
between the need for short-term profit and long-term stability and corporate 
research cultures. Additionally, RRI is, first and foremost, a European initiative, 
and while there have been attempts to promote RRI worldwide, including in the 
United States, China, Japan, India, Australia, and South Africa,49 the potential 
for global uptake and impact remains uncertain. In spite of its relative infancy 
and ongoing development, the business sector, including pharmaceutical compa-
nies, might benefit greatly from engagement with RRI.
Through engagement with RRI, pharmaceutical companies may find ways to 
move on from purely must and ought to levels of corporate responsibility to more 
effective and efficient adoption of can practices. The EC makes this clear with their 
declaration that RRI implies better alignment of the processes and outcomes of 
research and innovation with the values, needs and expectations of society,50 and, 
by inference, greater alignment with the SDGs. RRI extends a more conventional 
ethical review of research, and can be viewed as “creating opportunity.” The adop-
tion of RRI compels us to reflect upon the sort of future(s) we want science and 
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technology to bring to the world and how the aims and objectives of research and 
innovation can be identified in an ethical, inclusive, and equitable manner.51
Recent efforts to engage with the private sector52 to explore the perceived rele-
vance for them of RRI have resulted in highly positive feedback and the develop-
ment of tools that are specifically designed to aid practical implementation and 
action. For example, Stahl et al.53 have developed an easily applied RRI maturity 
model that is linked to corporate research and development processes. Such a 
model could be useful for organizations to understand and reflect on their current 
practice, to compare their activities with good industry practice, and to see where 
they could take action to achieve corporate responsibility excellence in their 
research and innovation activities.
Moving Forwards: Cocreation not Demarcation
When analyzing the responsibility performance of individual actors working in 
LMICs, we find a number of nonnegotiable good practices or duties that each 
actor is responsible for. Not everything that is legally allowed can be considered 
legitimate, and in the spirit of internationally accepted norms, the corporate 
responsibility of multinational pharmaceutical giants often goes beyond the letter 
of the law.54 In a low-income environment, this can mean taking charge of, and 
investing time and resources in, the management of issues that would not be con-
sidered as corporate duties in other environments (like the opening of access to 
unused product patents ).
No one stakeholder can assume responsibility for all necessary steps towards sus-
tainable development. While those with “broader shoulders” should carry a higher 
load, a division of labor, as envisaged by the Agenda 2030, is inevitable. A nation’s 
economic and social success is often at its greatest when there is cooperation involv-
ing a fair division of labor and responsibility among the different societal stakehold-
ers on the basis of shared values.55 It is constructive cocreation, not ideological 
demarcation, that leads to socio-economic progress on the basis of shared values.
Social systems of poverty consist of a number of undesirable conditions for 
work and life (low outputs and incomes, low productivity and conditions of pro-
duction, low quality of life, low aspirations toward life and work, unfavorable 
institutions, and inappropriate policies); these have been well described by Nobel 
Laureate Gunnar Myrdal.56 Such conditions are caught in a system of circular 
interdependence; a change in one will cause changes in the others, which leads to 
self-reinforcing processes of both a positive and a negative kind.
When discussing the ethical framework for clinical trials or other research in 
this context, it is reasonable to recall that a history of colonialism has much to do 
with the current state of poverty as well as the governance structures of many 
LMICs in which clinical trials are conducted. While it would be misguided to attri-
bute all socioeconomic evils and political irresponsibility in poor countries to past 
colonialism, it remains a fact that colonialism and its consequences have affected 
the nature of political and economic power, the structure of government and, in 
some cases, cultures of corruption. It also boosts the sensitivities of people who 
have been exploited by foreigners in the past. The “lows” referred to by Myrdal 
have their origin not in the local people’s unwillingness to work hard but in post-
colonial institutions and structures that continue to siphon resources away from 
the local areas, whether to wealthy local elites or to people in other countries.
ht
tp
s:
//
do
i.o
rg
/1
0.
10
17
/S
09
63
18
01
18
00
04
9X
D
ow
nl
oa
de
d 
fr
om
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e.
 U
ni
ve
rs
ity
 o
f C
en
tr
al
 L
an
ca
sh
ir
e,
 o
n 
10
 Ja
n 
20
19
 a
t 1
5:
15
:0
5,
 s
ub
je
ct
 to
 th
e 
C
am
br
id
ge
 C
or
e 
te
rm
s 
of
 u
se
, a
va
ila
bl
e 
at
 h
tt
ps
:/
/w
w
w
.c
am
br
id
ge
.o
rg
/c
or
e/
te
rm
s.
Symposium on Ethics Dumping
162
Working in social systems of poverty requires special care and diligence from 
corporations. As articulated in this paper, this demands attention to corporate 
responsibility at levels above the purely functional must requirements and even 
the desirable ought to responsibilities. Pharmaceutical corporations have a pivotal 
role to play in the cooperative action that is needed to achieve the ambitious SDGs, 
and there is clear evidence that some enlightened corporate leaders are already 
engaging with these responsibilities. However, this is not yet ubiquitous across all 
corporations, and the industry is still plagued by a general lack of trust. Trust is 
vital for effective collaborative actions, but it is also a valuable asset for all institu-
tions, and ongoing trust-building activities should be one of the most important 
strategic priorities for every organization.57 The adoption of RRI could prove to be 
an effective way of building trust in the research and innovation activities of phar-
maceutical companies with the assurance that such activities are socially accept-
able, desirable, and sustainable. Ultimately, to reach the goal of global health and 
wellbeing, pharmaceutical corporations must strive for corporate responsibility 
excellence, as nothing less will suffice.
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